Interest of the Dosage of Adalimumab Serum Levels in Crohn's Disease Patients for Prevention of Postoperative Recurrence (ADAPT)
Prospective, Controlled, Randomized, Multicentered, Open-label Study, Comparing 2 Modalities of Follow-up of Patients With Crohn's Disease, Postoperatively Treated With Adalimumab (Immunomonitoring vs Standard Follow-up)
Sponsor: University Hospital, Montpellier
Terminated
The recruitment of participants was no longer sufficient to continue the study.
Other terminated trials from University Hospital, Montpellier
A NA clinical study on Crohn Disease, this trial is terminated or withdrawn. The trial is conducted by University Hospital, Montpellier and has accumulated 10 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Feb 2025 — Present [monthly]
Terminated NA
Status: Unknown → Terminated
-
Nov 2024 — Feb 2025 [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Sep 2024 — Nov 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Nov 2022 — Jul 2024 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Jan 2021 — Nov 2022 [monthly]
Recruiting NA
-
May 2020 — Jan 2021 [monthly]
Recruiting NA
-
Mar 2020 — May 2020 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Feb 2020 — Mar 2020 [monthly]
Not Yet Recruiting NA
-
Jan 2020 — Feb 2020 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Montpellier
For direct contact, visit the study record on ClinicalTrials.gov .